Business Context and Reporting Period
This Form 8-K filing by Zimmer Biomet Holdings, Inc. (ZBH) is dated June 19, 2019. The report discloses a significant leadership transition within the company's executive management team, specifically regarding the Chief Financial Officer (CFO) role.
Key Financial Metrics
This filing does not contain operational financial results such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change reported is the departure of Daniel P. Florin, who is retiring as Executive Vice President and Chief Financial Officer. He will be succeeded by Suketu Upadhyay, effective July 1, 2019. Mr. Florin will remain in an advisory capacity during the transition. Mr. Upadhyay joins from Bristol-Myers Squibb Company, where he served as Senior Vice President, Global Financial Operations.
Management Commentary and Compensation Details
Mr. Upadhyay will serve as the new Principal Financial Officer and, temporarily, as the Principal Accounting Officer until a successor is found. His compensation package includes:
- Base Salary: $675,000 annualized.
- Annual Incentive: Target bonus of 90% of base salary (prorated for 2019).
- Long-Term Incentive (2020): Grant date fair value of approximately $2,400,000.
- Make-Whole Sign-On Bonus: $1,358,000 cash to replace forfeited compensation from his prior employer (subject to clawback if he leaves within two years).
- Make-Whole Equity Award: Grant date fair value of approximately $3,376,000 (50% stock options, 50% restricted stock units) to replace forfeited equity.
- Inducement Equity Award: Grant date fair value of approximately $500,000 in performance-based restricted stock units tied to Total Shareholder Return vs. S&P 500 Healthcare Index.
- Commuting Allowance: One-time payment of $252,000 (subject to clawback if he leaves within two years).
- Severance: Eligible for change-in-control and involuntary termination severance benefits under existing executive plans.
Investor Verification Checklist
- Verify the effective date of the CFO transition (July 1, 2019) and the interim status of the Principal Accounting Officer role.
- Review the total value of the sign-on compensation ($1,358,000 cash + $3,376,000 equity + $500,000 inducement equity + $252,000 allowance) and the associated clawback provisions.
- Confirm the vesting schedule for the make-whole equity award (25% per year over four years).
- Check the referenced press release (Exhibit 99.1) for additional strategic context regarding the leadership change.